Netflix, Vertex Pharmaceuticals And More On CNBC's 'Final Trades'

Important legal information about the email you will be sending. By using this service, you agree to input your real email address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an email. All information you provide will be used by Fidelity solely for the purpose of sending the email on your behalf. The subject line of the email you send will be "Fidelity.com: "

Netflix, Vertex Pharmaceuticals And More On CNBC's 'Final Trades'

, Benzinga - 8:27 AM ET 3/28/2025 default

On CNBC's “Halftime Report Final Trades,” Jim Lebenthal of Cerity Partners said he is long-term bullish but a bit nervous for the short term on Vertex Pharmaceuticals Incorporated ( VRTX ) .

RBC Capital analyst Brian Abrahams, on Feb. 20, maintained Vertex Pharmaceuticals ( VRTX ) with a Sector Perform rating and raised the price target from $407 to $408.

Shannon Saccocia of NB Private Wealth named iShares U.S. Financials ETF ( IYF ) as her final trade.

Don't forget to check out our premarket coverage here

Joshua Brown of Ritholtz Wealth Management picked Netflix, Inc. ( NFLX ) , saying the stock is close to its 52-week high.

Supporting his view, MoffettNathanson analyst Michael Nathanson, on March 17, upgraded Netflix ( NFLX ) from Neutral to Buy and raised the price target from $850 to $1100.

Price Action:

Vertex Pharmaceuticals ( VRTX ) shares gained 0.5% to close at $502.55 on Thursday.
iShares U.S. Financials ETF ( IYF ) fell 0.6% during Thursday's session.
Netflix ( NFLX ) shares gained 0.6% to close at $976.72 on Thursday.

Check This Out:

Jim Cramer: Stryker Is A ‘Good’ Company, Says He Likes This Utilities Stock

Photo: Shutterstock